The Predictive Value of Neuroendocrine Transcript Analysis in Daily Practice: An Independent ‘Real-World’ Validation Study

#2913

Introduction: Assessment of disease status remains the fundamental basis in the management of gastro-entero-pancreatic neuro-endocrine tumors (GEPNETs). Circulating molecular information might be used as a liquid biopsy to predict its clinical course.

Aim(s): We assessed the ability of the NETest®, a multi-analyte liquid biopsy quantifying gene expression in blood, in comparison with chromogranin A (CgA), for the prediction of disease status at follow-up.

Materials and methods: 152 patients with GEPNETs were followed for a median of 33 [6-52] months. NETest® score and CgA were measured at baseline. Disease status at follow-up was defined by RECIST 1.1. Radiologists and laboratory staff were blinded for diagnostic results. Optimal scores were estimated using ROC-curve analysis: low tumor activity (NETest ≤ 33%; CgA <140 µg/L), intermediate tumor activity (NETest 34-79%) and high tumor activity (NETest ≥ 80%; CgA ≥ 140 µg/L).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: van Treijen M

Authors: van Treijen M, van der Zee D, Heeres B, Staal F, Vriens M,

Keywords: biomarker, progression-free survival, gastro-entero-pancreatic neuroendocrine tumours,